This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dong, M. Articles by Dong, Y.-T. Search for Related Content PubMed PubMed Citation Articles by Dong, M. Articles by Dong, Y.-T.

Ki-ras Point Mutation and p53 Expression in Human Pancreatic Cancer: A Comparative Study among Chinese, Japanese, and Western Patients

First Department of Surgery, Shimane Medical University, Izumo 693-8501, Japan [M. D., Y. N., K. T.], and Second Department of Surgery, First Affiliated Hospital, China Medical University, Shenyang 110001, China [M. D., M-M. S., K-J. G., R-X. G., Y-T. D.]

The aim of this study was to clarify features of Ki-ras point mutation (PM) and p53 expression in Chinese pancreatic cancer and to compare those with that in other countries. Dot blot hybridization and immunohistochemical methods were performed in 59 Chinese patients. The results showed that Ki-ras PMs at codon 12 and p53 expression were frequent in this group. No relationships were found between Ki-ras PM alone and p53 expression alone, and clinicopathological parameters, including age, gender, clinical stage, and histological grade and classification in Chinese patients. However, their cooperation was significantly associated with a poor prognosis in this group. Comparison showed that there were significant differences in the overall frequency and substitution of Ki-ras PM and in the ratio of transition:transversion in pancreatic cancer among various countries. In addition, the effect of Ki-ras PM and p53 expression on a poor prognosis of pancreatic cancer may be different among various countries. These findings suggested that not only Ki-ras PM and p53 expression are frequent in Chinese pancreatic cancer, but also a gene component to pancreatic cancer may be different between Asian and Western pancreatic cancer. In addition, it seems that cooperation of Ki-ras PM and p53 expression may predict a poor prognosis in Chinese patients with pancreatic cancer.

This article has been cited by other articles:

				M. Abdelrahim, R. Smith III, R. Burghardt, and S. Safe Role of Sp Proteins in Regulation of Vascular Endothelial Growth Factor Expression and Proliferation of Pancreatic Cancer Cells Cancer Res., September 15, 2004; 64(18): 6740 - 6749. [Abstract] [Full Text] [PDF]

				A. B. Lowenfels and P. Maisonneuve Epidemiology and Prevention of Pancreatic Cancer Jpn. J. Clin. Oncol., May 1, 2004; 34(5): 238 - 244. [Abstract] [Full Text] [PDF]

				K. Yamasawa, Y. Nio, M. Dong, K. Yamaguchi, and M. Itakura Clinicopathological Significance of Abnormalities in Gadd45 Expression and Its Relationship to p53 in Human Pancreatic Cancer Clin. Cancer Res., August 1, 2002; 8(8): 2563 - 2569. [Abstract] [Full Text] [PDF]

				H. Han, D. J. Bearss, L. W. Browne, R. Calaluce, R. B. Nagle, and D. D. Von Hoff Identification of Differentially Expressed Genes in Pancreatic Cancer Cells Using cDNA Microarray Cancer Res., May 1, 2002; 62(10): 2890 - 2896. [Abstract] [Full Text] [PDF]

				H. C. King and A. A. Sinha Gene Expression Profile Analysis by DNA Microarrays: Promise and Pitfalls JAMA, November 14, 2001; 286(18): 2280 - 2288. [Abstract] [Full Text] [PDF]